fig 1 (IMAGE)

Compuscript Ltd

fig 1

Caption

Figure 1. Tumor suppressing pathways of LKB1. The LKB1-AMPK-mTOR pathway suppresses tumor development. LKB1-AMPK disrupt mTOR activity leading to decreased survival and proliferation while increasing autophagy. Pharmacological compounds that activate the LKB1-AMPK axis and are proven to suppress tumorigenesis include a tankyrase antagonist, metformin, and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Tankyrase antagonists enhance LKB1-STRAD-MO25 complex forming by blocking tankyrase-dependent ubiquitination (U) of LKB1. Metformin increases S428 LKB1 phosphorylation and AMP levels both promoting AMPK activation. AICAR also functions as an AMP mimetic to increase AMPK activity.

 

 

 

Credit

Genes & Diseases

Usage Restrictions

Credit must be given to the creator.

License

CC BY

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.